CoChat

Risk of Adverse Outcomes in Females Taking Oral Creatine Monohydrate: A Systematic Review and Meta-Analysis

Open access
de Guingand, Deborah L., Palmer, Kirsten R., Snow, Rodney J., Davies-Tuck, Miranda L., Ellery, Stacey J. · 2020 · Nutrients

The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.

Abstract

Creatine Monohydrate (CrM) is a dietary supplement routinely used as an ergogenic aid for sport and training, and as a potential therapeutic aid to augment different disease processes. Despite its increased use in recent years, studies reporting potential adverse outcomes of CrM have been mostly derived from male or mixed sex populations. A systematic search was conducted, which included female participants on CrM, where adverse outcomes were reported, with meta-analysis performed where appropriate. Six hundred and fifty-six studies were identified where creatine supplementation was the primary intervention; fifty-eight were female only studies (9%). Twenty-nine studies monitored for adverse outcomes, with 951 participants. There were no deaths or serious adverse outcomes reported. There were no significant differences in total adverse events, (risk ratio (RR) 1.24 (95% CI 0.51, 2.98)), gastrointestinal events, (RR 1.09 (95% CI 0.53, 2.24)), or weight gain, (mean difference (MD) 1.24 kg pre-intervention, (95% CI −0.34, 2.82)) to 1.37 kg post-intervention (95% CI −0.50, 3.23)), in CrM supplemented females, when stratified by dosing regimen and subject to meta-analysis. No statistically significant difference was reported in measures of renal or hepatic function. In conclusion, mortality and serious adverse events are not associated with CrM supplementation in females. Nor does the use of creatine supplementation increase the risk of total adverse outcomes, weight gain or renal and hepatic complications in females. However, all future studies of creatine supplementation in females should consider surveillance and comprehensive reporting of adverse outcomes to better inform participants and health professionals involved in future trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu12061780

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Organisation of article review process as a PRISMA 2009 flow diagram.
Figure 1 Organisation of article review process as a PRISMA 2009 flow diagram.CC BY · PubMed Central
Figure 2 Overall risk of bias for included studies. Data are presented as percentages of risk assessment across 7 predefined domains.
Figure 2 Overall risk of bias for included studies. Data are presented as percentages of risk assessment across 7 predefined domains.CC BY · PubMed Central
Figure 3 Individual risk of bias for included studies. Data are presented as risk assessment across 7 predefined domains. + (green)=low risk of bias, ? (yellow)=unclear risk of bias, - (red)=high risk of bias
Figure 3 Individual risk of bias for included studies. Data are presented as risk assessment across 7 predefined domains. + (green)=low risk of bias, ? (yellow)=unclear risk of bias, - (red)=high risk of biasCC BY · PubMed Central
Figure 4 Incidence of adverse events per participant, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Events = number of adverse events reported; Total = total number of participants in study group; Weight = amount of information contributed by study; M-H = Mantel–Haenszel model; Random= random effects model. Risk of bias; + (green) = low risk of bias, ? (yellow) = unclear risk of bias, - (red) = high risk of bias
Figure 4 Incidence of adverse events per participant, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Events = number of adverse events reported; Total = total number of participants in study group; Weight = amount of information contributed by study; M-H = Mantel–Haenszel model; Random= random effects model. Risk of bias; + (green) = low risk of bias, ? (yellow) = unclear risk of bias, - (red) = high risk of biasCC BY · PubMed Central
Figure 5 Incidence of gastrointestinal (GIT) events per participant, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Events = number of adverse events reported; Total = total number of participants in study group; Weight = amount of information contributed by study; M-H = Mantel-Haenszel model; Random=random effects model. Risk of bias; + (green) = low risk of bias, ? (yellow) = unclear risk of bias, - (red)=high risk of bias
Figure 5 Incidence of gastrointestinal (GIT) events per participant, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Events = number of adverse events reported; Total = total number of participants in study group; Weight = amount of information contributed by study; M-H = Mantel-Haenszel model; Random=random effects model. Risk of bias; + (green) = low risk of bias, ? (yellow) = unclear risk of bias, - (red)=high risk of biasCC BY · PubMed Central
Figure 6 Changes in renal blood biomarkers (A) and urine biomarkers (B) within placebo (solid bar) and CrM (hatched bar) groups. Data are presented as % change pre-to post-intervention. Units are expressed as presented in the original manuscripts. BUN = blood urea nitrogen, Alb:Crn = albumin:creatinine ratio.
Figure 6 Changes in renal blood biomarkers (A) and urine biomarkers (B) within placebo (solid bar) and CrM (hatched bar) groups. Data are presented as % change pre-to post-intervention. Units are expressed as presented in the original manuscripts. BUN = blood urea nitrogen, Alb:Crn = albumin:creatinine ratio.CC BY · PubMed Central
Figure 7 Changes in hepatic blood biomarkers within placebo (solid bar) and CrM (hatched bar) groups. Data are presented as % change pre- to post-intervention. Units are expressed as presented in the original manuscripts. ALP= alkaline phosphatase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = gamma glutamyl transferase.
Figure 7 Changes in hepatic blood biomarkers within placebo (solid bar) and CrM (hatched bar) groups. Data are presented as % change pre- to post-intervention. Units are expressed as presented in the original manuscripts. ALP= alkaline phosphatase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = gamma glutamyl transferase.CC BY · PubMed Central
Figure 8 (A) Difference in body weights per group, pre-intervention, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Mean = mean body weight per group in kgs; SD = standard deviation; Total = total number of participants in study group; Weight = amount of information contributed by study; I-V = Inverse Variance random effects model. (B) Difference in body weights per group, post-intervention, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Mean = mean body weight per group in kgs; SD = standard deviation; Total = total number of participants in study group; Weight = amount of information contributed by study; IV = Inverse variance model; Random=random effects model; Risk of bias; + (green) = low risk of bias, ? (yellow) = unclear risk of bias, - (red) = high risk of bias
Figure 8 (A) Difference in body weights per group, pre-intervention, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Mean = mean body weight per group in kgs; SD = standard deviation; Total = total number of participants in study group; Weight = amount of information contributed by study; I-V = Inverse Variance random effects model. (B) Difference in body weights per group, post-intervention, stratified by dosing regimens. Within Forest Plot, Study or Subgroup = study stratified by dosing regimens; Mean = mean body weight per group in kgs; SD = standard deviation; Total = total number of participants in study group; Weight = amount of information contributed by study; IV = Inverse variance model; Random=random effects model; Risk of bias; + (green) = low risk of bias, ? (yellow) = unclear risk of bias, - (red) = high risk of biasCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 174 references

Research works printed but not linked: 4

  1. Soltani Z. When “creatine” increases creatinine J. Investig. Med. 2011 59 459 460
  2. Kreider R.B. 6 Creatine Fears: Real Concern or False Alarm? Joe Weider’s Muscle Fit. 1999 60 160
  3. Earnest C. Almada A. Milchell T. Influence of chronic creatine supplementation on hepatorenal function FASEB J. 1996 10 3 A790
  4. Waldron J.E. Pendlay G.W. Kilgore T.G. Haff G.G. Reeves J.S. Kilgore J.L. Concurrent creatine monohydrate supplementation and resistance training does not affect markers of hepatic function in trained weightlifters J. Exerc. Physiol. Online 2002 5 57 64

Cited by

Metadata

Authors
de Guingand, D. L., Palmer, K. R., Snow, R. J., Davies-Tuck, M. L., & Ellery, S. J.
Affiliations
  • The Ritchie Centre, Hudson Institute of Medical Research, Melbourne 3168, Australia
  • Monash Medical Centre (AU)
  • Deakin University (AU)
  • Hudson Institute of Medical Research (AU)
Venue
Nutrients
Publisher
MDPI AG
Published
2020-06-15
Volume
12
Issue
6
Pages
1780
ISSN
2072-6643 (ISSN-L)
OpenAlex
W3035089779
Cited by
35
References
171
Citations by year
2026: 3 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 11 · 2020: 2
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Monash University
  • State Government of Victoria
  • Hudson Institute of Medical Research
  • National Health and Medical Research Council
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutrition and Health Studies
  • Health Sciences › Medicine › Physiology (medical) › Biochemical effects in animals
Keywords
creatine monohydrate, dietary supplements, adverse events, gastrointestinal adverse effects, weight gain, renal function, liver function, ergogenic aids
MeSH terms
Adult, Aged, Body Composition, Creatine, Female, Gastrointestinal Diseases, Humans, Liver Diseases, Middle Aged, Weight Gain, Risk Assessment, Dietary Supplements, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.